1. Home
  2. ADCT vs FACT Comparison

ADCT vs FACT Comparison

Compare ADCT & FACT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ADCT
  • FACT
  • Stock Information
  • Founded
  • ADCT 2011
  • FACT 2024
  • Country
  • ADCT Switzerland
  • FACT United States
  • Employees
  • ADCT N/A
  • FACT N/A
  • Industry
  • ADCT Biotechnology: Pharmaceutical Preparations
  • FACT
  • Sector
  • ADCT Health Care
  • FACT
  • Exchange
  • ADCT Nasdaq
  • FACT NYSE
  • Market Cap
  • ADCT 241.0M
  • FACT 245.6M
  • IPO Year
  • ADCT 2020
  • FACT 2024
  • Fundamental
  • Price
  • ADCT $2.97
  • FACT $10.17
  • Analyst Decision
  • ADCT Strong Buy
  • FACT
  • Analyst Count
  • ADCT 5
  • FACT 0
  • Target Price
  • ADCT $7.75
  • FACT N/A
  • AVG Volume (30 Days)
  • ADCT 694.8K
  • FACT 17.2K
  • Earning Date
  • ADCT 05-14-2025
  • FACT 01-01-0001
  • Dividend Yield
  • ADCT N/A
  • FACT N/A
  • EPS Growth
  • ADCT N/A
  • FACT N/A
  • EPS
  • ADCT N/A
  • FACT N/A
  • Revenue
  • ADCT $75,817,000.00
  • FACT N/A
  • Revenue This Year
  • ADCT $9.19
  • FACT N/A
  • Revenue Next Year
  • ADCT $16.27
  • FACT N/A
  • P/E Ratio
  • ADCT N/A
  • FACT N/A
  • Revenue Growth
  • ADCT 10.49
  • FACT N/A
  • 52 Week Low
  • ADCT $1.05
  • FACT $9.85
  • 52 Week High
  • ADCT $4.13
  • FACT $10.32
  • Technical
  • Relative Strength Index (RSI)
  • ADCT 75.65
  • FACT N/A
  • Support Level
  • ADCT $1.83
  • FACT N/A
  • Resistance Level
  • ADCT $2.35
  • FACT N/A
  • Average True Range (ATR)
  • ADCT 0.31
  • FACT 0.00
  • MACD
  • ADCT 0.12
  • FACT 0.00
  • Stochastic Oscillator
  • ADCT 93.03
  • FACT 0.00

About ADCT ADC Therapeutics SA

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).

About FACT FACT II ACQUISITION CORP

FACT II Acquisition Corp is a blank check company.

Share on Social Networks: